X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
proto-oncogene proteins pp60 - metabolism (380) 380
animals (339) 339
humans (322) 322
phosphorylation (233) 233
proto-oncogene proteins pp60 - antagonists & inhibitors (223) 223
index medicus (182) 182
biochemistry & molecular biology (155) 155
mice (155) 155
signal transduction (148) 148
cell biology (134) 134
enzyme inhibitors - pharmacology (127) 127
cells, cultured (113) 113
rats (113) 113
activation (107) 107
c-src (102) 102
proto-oncogene proteins pp60 - genetics (102) 102
phosphorylation - drug effects (94) 94
oncology (93) 93
src (90) 90
signal transduction - drug effects (86) 86
cell line, tumor (81) 81
protein-tyrosine kinases - metabolism (80) 80
expression (79) 79
cell line (74) 74
protein-tyrosine kinases - antagonists & inhibitors (74) 74
male (73) 73
enzyme activation (69) 69
protein kinase inhibitors - pharmacology (69) 69
female (66) 66
tyrosine - metabolism (64) 64
pyrimidines - pharmacology (63) 63
enzyme activation - drug effects (61) 61
proto-oncogene proteins pp60 - physiology (61) 61
tyrosine kinase (61) 61
cancer (55) 55
tyrosine phosphorylation (55) 55
article (53) 53
blotting, western (52) 52
amino acid sequence (51) 51
molecular sequence data (50) 50
research (50) 50
tumor cells, cultured (50) 50
src-family kinases - metabolism (46) 46
transfection (46) 46
src-family kinases - antagonists & inhibitors (45) 45
kinases (44) 44
proteins (44) 44
phosphatidylinositol 3-kinases - metabolism (42) 42
receptor, epidermal growth factor - metabolism (42) 42
signal transduction - physiology (42) 42
proto-oncogene proteins c-akt - metabolism (41) 41
mitogen-activated protein kinases - metabolism (40) 40
protein binding (40) 40
apoptosis (39) 39
cell proliferation - drug effects (38) 38
dose-response relationship, drug (37) 37
mitogen-activated protein kinase 1 - metabolism (37) 37
binding sites (36) 36
kinetics (36) 36
signal-transduction (36) 36
cell movement - drug effects (35) 35
endocrinology & metabolism (35) 35
protein (35) 35
focal adhesion kinase (34) 34
apoptosis - drug effects (33) 33
phosphotyrosine - metabolism (33) 33
protein kinase c - metabolism (33) 33
proto-oncogene proteins pp60 - chemistry (33) 33
rats, sprague-dawley (33) 33
cells (32) 32
research article (32) 32
structure-activity relationship (32) 32
time factors (32) 32
extracellular signal-regulated map kinases - metabolism (31) 31
ligands (30) 30
physiology (30) 30
actins - metabolism (29) 29
family kinases (29) 29
growth-factor (29) 29
mutation (29) 29
phosphoproteins - metabolism (29) 29
proto-oncogene proteins - metabolism (29) 29
tyrosine (29) 29
antineoplastic agents - pharmacology (28) 28
biophysics (28) 28
growth-factor receptor (28) 28
kinase (28) 28
mitogen-activated protein kinase 3 - metabolism (28) 28
substrate specificity (28) 28
health aspects (27) 27
in-vivo (27) 27
models, biological (27) 27
phosphatidylinositol 3-kinases - antagonists & inhibitors (27) 27
cell proliferation (26) 26
pp60c-src (26) 26
receptor (26) 26
analysis (25) 25
calcium - metabolism (25) 25
cell division - drug effects (25) 25
metastasis (25) 25
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Science, ISSN 0036-8075, 12/2014, Volume 346, Issue 6216, pp. 1480 - 1486
Targeted cancer therapies have produced substantial clinical responses, but most tumors develop resistance to these drugs. Here, we describe a pharmacogenomic... 
CELL LUNG-CANCER | ALK | KINASE INHIBITION | GEFITINIB | ACTIVATION | CERITINIB | MULTIDISCIPLINARY SCIENCES | CRIZOTINIB | MUTATIONS | CHEMOTHERAPY | BYPASS MECHANISMS | Lung Neoplasms - drug therapy | Sulfones - therapeutic use | Humans | Receptor, Fibroblast Growth Factor, Type 3 - antagonists & inhibitors | MAP Kinase Kinase 1 - genetics | DNA Mutational Analysis | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Tumor Cells, Cultured | Molecular Targeted Therapy - methods | Lung Neoplasms - genetics | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | MAP Kinase Kinase 1 - metabolism | Proto-Oncogene Proteins pp60(c-src) - antagonists & inhibitors | Patient-Specific Modeling | Drug Resistance, Neoplasm - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Enzyme Activation - genetics | Drug Screening Assays, Antitumor | Antimitotic agents | Cancer patients | Care and treatment | Lung cancer | Dosage and administration | Genetic aspects | Antineoplastic agents | Drug therapy | Drug resistance | Methods | Cancer | Cell culture | Oncology | Pharmaceutical sciences | Drugs | Mutations | Therapy | Genetics | Kinases | Patients | Tumors
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 1/2013, Volume 110, Issue 5, pp. 1664 - 1669
Tyrosine kinases present attractive drug targets for specific types of cancers. Gleevec, a well-known therapeutic agent against chronic myelogenous leukemia,... 
Molecules | Thermodynamics | Solvents | Roux | Molecular dynamics | Atoms | Ligands | Chronic myeloid leukemia | Electrostatics | Free energy | Sampling | Alchemical free energy perturbation | CHRONIC MYELOGENOUS LEUKEMIA | BINDING FREE-ENERGY | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | sampling | BCR-ABL | thermodynamics | alchemical free energy perturbation | HISTOGRAM ANALYSIS METHOD | CHRONIC MYELOID-LEUKEMIA | INACTIVE CONFORMATION | RESTRAINING POTENTIALS | MOLECULAR-DYNAMICS SIMULATIONS | C-SRC | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Crystallography, X-Ray | Piperazines - metabolism | Proto-Oncogene Proteins pp60(c-src) - chemistry | Pyrimidines - metabolism | Binding Sites | Binding, Competitive | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Protein Structure, Tertiary | Proto-Oncogene Proteins c-abl - chemistry | Models, Molecular | Proto-Oncogene Proteins pp60(c-src) - antagonists & inhibitors | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Proto-Oncogene Proteins pp60(c-src) - metabolism | Protein Binding | Proto-Oncogene Proteins c-abl - metabolism | Protein Conformation | Protein Kinase Inhibitors - pharmacology | Benzamides | Protein Kinase Inhibitors - metabolism | Tyrosine | Physiological aspects | Research | Phosphotransferases | Health aspects | Protein binding | Biological Sciences | Physical Sciences
Journal Article
Molecular Biology of the Cell, ISSN 1059-1524, 01/2008, Volume 19, Issue 1, pp. 394 - 404
Journal Article
Oncogene, ISSN 0950-9232, 04/2018, Volume 37, Issue 16, pp. 2104 - 2121
Journal Article
Journal Article
Cell, ISSN 0092-8674, 2007, Volume 128, Issue 2, pp. 281 - 294
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2012, Volume 18, Issue 1, pp. 127 - 139
Purpose: The inhibition of c-Src results in a striking reduction in cancer cell invasion, but the effect on cell survival is modest. Defining mechanisms that... 
EPITHELIAL-MESENCHYMAL TRANSITION | BREAST-CANCER | LUNG-CANCER | ONCOLOGY | CONSTITUTIVE ACTIVATION | INTESTINAL GROWTH | EPIDERMAL-GROWTH-FACTOR | IN-VIVO | CELL-CYCLE ARREST | TYROSINE KINASES | SIGNAL TRANSDUCER | RNA, Small Interfering - genetics | Immunoprecipitation | Tumor Suppressor Proteins - antagonists & inhibitors | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Head and Neck Neoplasms - metabolism | Immunoenzyme Techniques | STAT5 Transcription Factor - genetics | STAT5 Transcription Factor - metabolism | Janus Kinase 2 - metabolism | STAT5 Transcription Factor - antagonists & inhibitors | Tumor Suppressor Proteins - genetics | Female | Tumor Cells, Cultured | Real-Time Polymerase Chain Reaction | STAT3 Transcription Factor - genetics | STAT3 Transcription Factor - metabolism | Head and Neck Neoplasms - prevention & control | Tumor Suppressor Proteins - metabolism | RNA, Messenger - genetics | Janus Kinase 2 - genetics | Suppressor of Cytokine Signaling Proteins - genetics | Proto-Oncogene Proteins pp60(c-src) - antagonists & inhibitors | Carcinoma, Squamous Cell - prevention & control | Blotting, Western | Animals | Mice, Nude | Proto-Oncogene Proteins pp60(c-src) - genetics | Proto-Oncogene Proteins pp60(c-src) - metabolism | Suppressor of Cytokine Signaling Proteins - antagonists & inhibitors | Head and Neck Neoplasms - genetics | Mice | Suppressor of Cytokine Signaling Proteins - metabolism | SOCS2 | STAT5 | Src | JAK | STAT3
Journal Article
American Journal of Respiratory Cell and Molecular Biology, ISSN 1044-1549, 2014, Volume 50, Issue 3, pp. 559 - 570
The diagnosis of chronic obstructive pulmonary disease (COPD) confers a 2-fold increased lung cancer risk even after adjusting for cigarette smoking,... 
Phosphorylation | Inflammation | Kinase | Cell signaling | Epithelial | CELLS | METASTASIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | epithelial | CANCER | CELL BIOLOGY | kinase | OBSTRUCTIVE PULMONARY-DISEASE | inflammation | RESPIRATORY SYSTEM | ELASTASE | cell signaling | EPIDERMAL-GROWTH-FACTOR | MATRIX-METALLOPROTEINASE-9 | MICE | INDUCED EMPHYSEMA | phosphorylation | EXPRESSION | Smoking - adverse effects | Protein Kinase C-alpha - metabolism | Epithelial Cells - drug effects | Humans | Pneumonia - pathology | Pneumonia - prevention & control | Pulmonary Disease, Chronic Obstructive - etiology | Pulmonary Disease, Chronic Obstructive - pathology | Case-Control Studies | Lung - enzymology | Dose-Response Relationship, Drug | Receptor, Epidermal Growth Factor - metabolism | Transfection | RNA Interference | Time Factors | Inflammation Mediators - metabolism | Disease Models, Animal | Pneumonia - genetics | Pulmonary Disease, Chronic Obstructive - genetics | Lung - pathology | Pneumonia - etiology | Cytokines - metabolism | Neutrophils - enzymology | Pneumonia - enzymology | Smoke - adverse effects | Mice, Inbred C57BL | Neutrophils - drug effects | Cells, Cultured | Epithelial Cells - pathology | Proto-Oncogene Proteins pp60(c-src) - antagonists & inhibitors | Proto-Oncogene Proteins c-raf - metabolism | Macrophages - enzymology | Pulmonary Disease, Chronic Obstructive - enzymology | Monocytes - drug effects | Monocytes - enzymology | Animals | Signal Transduction - drug effects | Pulmonary Disease, Chronic Obstructive - prevention & control | Lung - drug effects | Proto-Oncogene Proteins pp60(c-src) - genetics | Proto-Oncogene Proteins pp60(c-src) - metabolism | Epithelial Cells - enzymology | Macrophages - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Enzyme Activation | Mitogen-Activated Protein Kinases - metabolism | Cell culture | Disease | Lung cancer | Mortality | Kinases | Cigarettes | Cell adhesion & migration | Proteins | Studies | Signal transduction | Epidermal growth factor | Chronic obstructive pulmonary disease | Original Research
Journal Article
Hypertension, ISSN 0194-911X, 06/2012, Volume 59, Issue 6, pp. 1263 - 1271
Journal Article
Cancer Letters, ISSN 0304-3835, 2016, Volume 379, Issue 1, pp. 12 - 23
The Highlights of Our Study • Phosphoryalted caspase-8 by c-Src was screened out by protein microarray to predict the poorer disease-free and overall survival... 
Hematology, Oncology and Palliative Medicine | Dasatinib | Lung adenocarcinoma | Necroptosis | Paclitaxel | ADJUVANT CHEMOTHERAPY | RIP KINASES | SURVIVAL | APOPTOSIS | MECHANISM | CANCER | CELL-DEATH | PROTEOME CHIPS | NECROSIS | ONCOLOGY | INHIBITOR | Receptor-Interacting Protein Serine-Threonine Kinases - metabolism | Lung Neoplasms - drug therapy | Phosphorylation | Adenocarcinoma - pathology | Paclitaxel - pharmacology | Adenocarcinoma of Lung | Apoptosis - drug effects | Humans | Middle Aged | Caspase 8 - metabolism | Lung Neoplasms - pathology | Male | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Necrosis | Caspase 8 - genetics | Transfection | RNA Interference | Time Factors | Female | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Tyrosine | A549 Cells | Lung Neoplasms - enzymology | Adenocarcinoma - enzymology | Kaplan-Meier Estimate | Treatment Outcome | Proto-Oncogene Proteins pp60(c-src) - antagonists & inhibitors | Cisplatin - pharmacology | Adenocarcinoma - drug therapy | Paclitaxel - therapeutic use | Dasatinib - pharmacology | Pregnancy | Xenograft Model Antitumor Assays | Disease-Free Survival | Receptor-Interacting Protein Serine-Threonine Kinases - genetics | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Proto-Oncogene Proteins pp60(c-src) - genetics | Proto-Oncogene Proteins pp60(c-src) - metabolism | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Adenocarcinoma | Antineoplastic agents | Proteins | Antigens | Immunoglobulins | Chemotherapy | Lung cancer | Metastasis | Kinases | Cancer therapies | Apoptosis | Tumors
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 07/2007, Volume 6, Issue 7, pp. 1962 - 1972
Journal Article